NASDAQ: NMADNomad Power Solutions Inc Stock
$6.10-1.24 (-16.89%)
Updated Jul 7, 2026
NMAD Price
$6.10
Fair Value Price
$0.09
Market Cap
$75.54M
52 Week Low
$2.36
52 Week High
$8.38
P/E
-5.35x
P/B
9.51x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.22M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$4M
Beta
0.83
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NMAD Overview
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NMAD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NMAD
Ranked#133 of 462
Ranked#133 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $247.72 | A | |
| $10.34 | A | |
| $16.22 | A |
Be the first to know about important NMAD news, forecast changes, insider trades & much more!
NMAD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NMAD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NMAD ($6.10) is overvalued by 6,546.99% relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NMAD ($6.10) is not significantly undervalued (6,546.99%) relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NMAD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NMAD due diligence checks available for Premium users.
Valuation
NMAD fair value
Fair Value of NMAD stock based on Discounted Cash Flow (DCF)
Price
$6.10
Fair Value
$0.09
Overvalued by
6,546.99%
NMAD ($6.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NMAD ($6.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NMAD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NMAD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.35x
Industry
17.73x
Market
8.58x
NMAD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.51x
Industry
5.67x
NMAD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NMAD's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
NMAD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.9M
Liabilities
$1.7M
Debt to equity
0.21
NMAD's short-term assets ($3.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NMAD's short-term assets ($3.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NMAD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NMAD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
-$24.9k
Financing
$0.0
NMAD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NMAD vs Biotech Stocks
Nomad Power Solutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.